RPE65 and Retinal dystrophy: As the first US FDA approved gene therapy for monogenic diseases, LUXTURNA® received approval in 2017 in the United States and subsequently in Canada and Australia in 2020 for treating Biallelic RPE65 mutation‐associated retinal dystrophy.